MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Jul 28, 2001 - Glaxo: 1HFY02 PBT drops 34%
Glaxo: 1HFY02 PBT drops 34%
Glaxo has reported a sharp drop in sales and PBT for 2QFY02. The results declared by the company were more or less expected by the markets. There is an one time charge of Rs 75 m in 2QFY02 on account of expenses of new launches and restructuring expenses in relation with amalgamation of SmithKline Beecham. Though operating margins have dropped at the look of it, after adjusting for one time charges, the operating margins have remained stable.
| (Rs m) | 1HFY01 | 1HFY02 | %Change | 2QFY01 | 2QFY02 | %Change |
| Sales | 4,700 | 3,927 | -16.5% | 2,867 | 1,983 | -30.8% |
| Other Income | 161 | 147 | -8.6% | 81 | 83 | 3.0% |
| Expenditure | 4,244 | 3,631 | -14.4% | 2,555 | 1,850 | -27.6% |
| Operating Profit (EBDIT) | 456 | 296 | -35.2% | 312 | 133 | -57.4% |
| Operating Profit Margin (%) | 9.7% | 7.5% | 10.9% | 6.7% | ||
| Interest | 47 | 42 | -9.0% | 26 | 20 | -23.7% |
| Depreciation | 77 | 74 | -4.8% | 38 | 36 | -5.8% |
| Profit before Tax | 493 | 327 | -33.8% | 329 | 161 | -51.2% |
| Extraordinary Income | 155 | 394 | 105 | 394 | ||
| Tax | 212 | 193 | -9.0% | 139 | 129 | -7.3% |
| Profit after Tax/(Loss) | 436 | 527 | 20.8% | 295 | 425 | 44.1% |
| Net profit margin (%) | 9.3% | 13.4% | 10.3% | 21.4% | ||
| No. of Shares (eoy) (m) | 60 | 60 | 60 | 60 | ||
| Diluted Earnings per share* | 14.6 | 17.6 | 19.7 | 28.4 | ||
| P/E (at current price) | 14.4 | 8.9 | ||||
| (*- annualised) |
The decline in turnover can largely be attributed to drop in sales of Ceftum, Cobadex, Forte and Betnesol, the key products for the company. The company has identified 30 strategic key brands, which contributes around 75% of the total turnover. The promotion expenses would be restricted to brands that have potential to provide growth momentum. Going forward, the company also plans to have tighter control over its administrative costs. Glaxo has recently launched an anti asthma (Seretide) an anti-allergy drug (Flixonase) and an smoking cessation pill (Zyban).
At the current market price of Rs 253, the stock is trading at a P/e of 12x its expected earnings for FY02. The company is expected to benefit on account of cost savings from amalgamation with SmithKline Pharma.
More Views on News
GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)
Oct 30, 2020 | Updated on Oct 30, 2020For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)
Apr 6, 2021Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
A Unique Sector for Short-Term Profits (Fast Profits Daily)
Apr 12, 2021This ignored sector could deliver big short-term profits.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
GSK PHARMA SHARE PRICE
Apr 19, 2021 09:48 AM
TRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA 8-QTR ANALYSIS
COMPARE GSK PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "Glaxo: 1HFY02 PBT drops 34%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!